Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative parecoxib for postoperative pain after esophageal ESD
ChiCTR2400080433Phase 4Not yet recruiting
- Sponsor
- Shiyan Taihe Hospital
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of parecoxib in esophageal cancer (2 arms), sponsored by Shiyan Taihe Hospital. Primary endpoints: Postoperative pain, Serum C-reactive protein and 2 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
parecoxib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2400080433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080433.